



(1) Division of Intramural Research, NIAID, NIH, Baltimore, MD, United States; (2) Dept. of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; (3) Rakai Health Sciences Program, Entebbe, Uganda; (4) Dept. of Medicine, Johns Hopkins School of Medicine, Baltimore, United States; (5) Dept. of Pathology, Johns Hopkins School of Medicine, Baltimore, United States

Background

Medical male circumcision (MC) decreases heterosexual acquisition of HIV and herpes simplex virus type 2 (HSV-2).¹

Penile HIV shedding increases in the first 1-3 weeks following MC in ART-naïve men,² and penile HSV-2 shedding increases in the first 1-2 weeks post-MC in HIV/HSV-2 co-infected men.³

This study aimed to characterize the pro-inflammatory response associated with penile HIV and HSV-2 shedding from MC wounds in HIV positive Ugandan men.

Methodology

Study Design

A prospective study of HIV-infected men undergoing MC was conducted in Rakai, Uganda. Non-traumatic penile lavage samples using PBS were collected at the coronal sulcus prior to MC, and weekly post-MC for 4 weeks.

Laboratory Testing

HIV shedding status (HIV VL >40 copies/mL) was previously assessed from all available penile lavage samples, and penile HSV-2 shedding status (DNA >50 copies/mL) was previously assessed among men seropositive for HSV-2.

Lavages were tested for pro-inflammatory cytokines (IFN- γ , IL-10, IL-12p70, IL-13, IL-1 β , IL-2, IL-4, IL-6, IL-8, and TNF- α) by a multiplex electrochemiluminescence immunoassay (Meso Scale Discovery Inc.). Samples were tested in duplicate within a plate, and were considered detectable if detected in both wells. Samples above detection were set to the ULQ per plate. Cytokines with <1% detectability were excluded from analyses: IFN-γ, IL-12p70, & IL-4.

Statistical Analyses

The probability of cytokine detection post-MC was examined relative to the pre-surgical visit, and analyses were stratified by plasma HIV viral suppression status (VL<400 copies/mL).

Analyses of penile HIV shedding were limited to men with detectable plasma HIV VL at enrollment. Prevalence risk ratios (PRRs) of HIV or HSV-2 shedding at post-surgical visits were estimated using Poisson regression models with generalized estimating equations and robust variance Multivariate models included adjustment for estimation. confounders: study visit and penile HIV/HSV-2 potential status. Detectable log₁₀ cytokine levels were shedding compared by shedding status using rank sum tests.

Genital Inflammation and HIV/HSV-2 Shedding Post-Male Circumcision in Rakai, Uganda

Eshan U. Patel,^{1,2} M. Kate Grabowski,^{2,3} Godfrey Kigozi,³ Ronald H. Gray,^{2,3} Andrew D. Redd,^{1,4} Allison R. Kirkpatrick,¹ David Serwadda,³ Maria J. Wawer,^{2,3} Thomas C. Quinn,^{1,2,4,5} Aaron A. R. Tobian^{2,3,4,5}

Results

Baseline characteristics Tahla 1

Table I. Dasenne characteristics.				$\underline{\text{Table } L}$								
	Detectable Suppressed Plasma HIV VL Plasma HIV VL (n=175) (n=46)		Cytokine Detection		HIV Shedding Among Men with Detectable Plasma HIV VL			HSV-2 Shedding Among All Men				
Characteristic					% HIV Shed (no. visits/total)	PRR (95% CI)	adj-PRR (95% CI)	% HSV-2 Shed (no. visits/total)	PRR (95% CI)	adj-PRR (95% CI)		
Age, years						ſ			C	C		
<30	38.3% (67)	58.7% (27)	II -2	no	17.6% (106/601)	ret.	ret.	11.1% (66/595)	ref.	ret.		
30-39	42.9% (75)	26.1% (12)		yes	43.6% (14/32)	2.48 (1.51, 4.08) [‡]	2.12 (1.57, 3.87) [†]	14.3% (4/28)	1.29 (0.43, 3.82)	1.19 (0.39, 3.61)		
≥40	18.9% (33)	15.2% (7)		no	17.4% (104/598)	ref.	ref.	11.0% (65/590)	ref.	ref.		
CD4 ⁺ T-cell count, cells/μL			IL-10	ves	45.7% (16/35)	2.63 (1.58, 4.38) [‡]	1.87 (0.97, 3.58)	15.2% (5/33)	1.38 (0.53, 3.55)	1.20 (0.33, 1.71)		
<200	41.1% (72)	39.1% (18)		no	13 4% (56/417)	rof	rof	10.6% (13/103)	rof	rof		
200-299	46.3% (81)	47.8% (22)	IL-13	ΠΟ	13.4 /0 (30/417)			10.0 % (43/403)				
≥300	12.6% (22)	13.0% (6)		yes	29.6% (64/216)	2.21 (1.60, 3.03) ⁷	1.82 (1.18, 2.80) <i>‡</i>	12.3% (27/220)	1.15 (0.71, 1.87)	0.90 (0.52, 1.57)		
GUD During Last 30 days			11 40	no	4.3% (6/140)	ref.	ref.	6.2% (9/146)	ref.	ref.		
No	84.6% (148)	93.5% (43)	і∟-тр	yes	23.1% (114/493)	5.40 (1.78, 16.37) [‡]	3.73 (1.17, 11.94) <i>‡</i>	12.8% (61/477)	2.07 (1.06, 4.07)*	1.66 (0.82, 3.39)		
Yes	15.4% (27)	6.5% (3)		no	10.5% (35/332)	ref.	ref.	8.8% (29/329)	ref.	ref.		
Penile HSV-2 Shedding Status [#]			IL-6		20.20/(05/201)	269(192202)t	2 22 (1 22 2 72) t	14 00/ (41/204)	1 59 (0 04 2 67)			
No	91.3% (126)	86.1% (31)		yes	20.2% (00/301)	2.00 (1.03, 3.92)*	∠.∠3 (1.33, 3.7∠) ⁺	14.0% (41/294)	1.56 (0.94, 2.07)	1.31(0.71, 2.43)		
Yes	8.7% (12)	13.9% (5)		no	13.9% (69/498)	ref.	ref.	11.2% (54/484)	ref.	ref.		
Penile HIV Shedding Status				yes	37.8% (51/135)	2.73 (1.98, 3.75) [‡]	2.17 (1.43, 3.28) [‡]	11.5 % (16/139)	1.03 (0.55, 1.95)	0.87 (0.43, 1.76)		
No	90.1% (159)	97.8% (45)		no	4.6% (6/131)	ref.	ref.	4.4% (6/138)	ref.	ref.		
Yes	9.1% (16)	2.2% (1)	IL-8	yes	22.7% (114/502)	4.96 (1.65, 14.89) [‡]	3.48 (1.11, 10.94) [†]	13.2% (64/485)	3.04 (1.35, 6.80) [‡]	2.56 (1.11, 5.88) [†]		
Self-Report ART Use			Multivor	j ioto mo	dole wore adjusted for	r notantial confoundars	datarminad a priori: stud	visit and popilo HIV/	JSV/2 shodding status	$t P < 0.05 \cdot t P < 0.01$		
No	93.7% (164)	37.0% (17)	wuuvar			polential comounders o	determined a priori. Study		13 V-2 Sheuuniy Status	. 'F < 0.03, + F < 0.01		
Yes	6.3% (11)	63.0% (29)	Table 3	B. Ass	sociation betwee	n the number of c	ytokines detected	and HIV or HSV-	2 shedding from	MC wounds.		
Median HIV log ₁₀ VL. c/mL (IQR)	4.6 (4.2-5.2)	_					-		~			

[#] Penile HSV-2 shedding was not previously assessed in 37 HIV viremic and 10 HIV suppressed men.

Figure 1. Probability of cytokine detection by visit.







- Baseline CD4⁺ T-cell count and genital ulcer disease (GUD) were not associated with cytokine detection.
- Certified healed wounds post-MC were associated with a decrease in cytokine detection (except IL-2 & IL-10).

% Visits with Cytokine Detected -100 -80 -60 -40 -20

Results (cont.)

Table 2 Cytokine detection associated with HIV and HSV-2 shedding from MC wounds

No.	HIV Shedding Ar	mong Men with Detecta	able Plasma HIV VL	HSV-2 Shedding Among All Men			
Cytokines Detected	% HIV Shed (no. visits/total)	PRR (95% CI)	adj-PRR (95% CI)	% HSV-2 Shed (no. visits/total)	PRR (95% CI)	adj-PRR (95% CI)	
0-1	3.9% (6/153)	ref.	ref.	5.6% (9/161)	ref.	ref.	
2-4	18.5% (66/356)	4.73 (1.54, 14.52) <i>‡</i>	3.54 (1.11, 11.25) <i>†</i>	13.9% (47/338)	2.48 (1.25, 4.96)*	2.02 (0.99, 4.12)	
5-7	37.7% (48/161)	9.61 (3.15, 29.35) [‡]	7.34 (2.23, 24.09) [‡]	10.9% (14/129)	1.94 (0.82, 4.58)	1.49 (0.58, 3.83)	
	dele sueve e dissete d'fer				O(2) also delivery statics		

Multivariate models were adjusted for potential confounders determined a priori: study visit and penile HIV/HSV-2 shedding status. TP<0.05; P<0.01

Figure 2. Cytokine levels by HIV shedding status.



 Among samples with detectable cytokines, higher levels of \log_{10} IL-1 β and IL-8 were associated with HIV shedding (Fig. 2), but no significant differences in cytokine concentrations were observed by HSV-2 shedding status.

Detectability of pro-inflammatory cytokines increased following MC but returned to baseline levels by 4 weeks.

Pro-inflammatory cytokines (IL-1 β , IL-6, IL-8, IL-13 and TNF- α) were associated with penile HIV shedding, and IL-8 was also associated with penile HSV-2 shedding post-MC.

HIV- and HSV-2-infected men should be counseled on the risk of HIV and HSV-2 transmission prior to wound healing, highlighting the need for sexual abstinence during wound healing and consistent condom use thereafter.





Abstract #987 Eshan U. Patel MPH Candidate 855 North Wolfe St, Rangos Bldg, Rm 538A altimore, MD 21205 epatel6@jhmi.edu

Conclusions

Acknowledgements: This study was supported by the Bill and Melinda Gates Foundation (22006.03, sample collection), the Doris Duke Charitable Foundation (#2011036 for lab work and Clinician Scientist Development awards to M. K. G. and A. A. R. T.), and the Fogarty International Center (1D43TWOO9578-01). The presented work was supported by the Division of Intramural Research, NIAID, NIH, and by extramural NIH funding (grants T32AI102 supported M. K. G. and 1K23AI093152-01A1 to A. A. R. T.).

References: [1] Tobian AA et al. Annual review of medicine. 2014;65:293. [2] Tobian AA et al. PLoS Medicine 2015 Apr 28;12(4):e1001820. [3] Grabowski MK et al. Journal of Infectious Diseases. 2015 Nov 15;212(10):1613-7.